Insightful Word
  • Investing
  • Stock
  • Economy
  • Politics
  • Investing
  • Stock
  • Economy
  • Politics
No Result
View All Result
Insightful Word
No Result
View All Result
Home Stock

3 reasons Bernstein strategists are bullish on the EU pharma sector into 2025

admin by admin
January 12, 2025
in Stock
0
3 reasons Bernstein strategists are bullish on the EU pharma sector into 2025
0
SHARES
5
VIEWS
Share on FacebookShare on Twitter

Investing.com — Bernstein analysts are optimistic about the European pharmaceutical sector as it heads into 2025, despite concerns over policy changes and market headwinds. 

The firm outlined its three key reasons for the positive outlook in a note this week

Solid Growth Prospects: Bernstein forecasts an 8% EPS compound annual growth rate (CAGR) from 2025 to 2030, excluding Novo Nordisk (NYSE:NVO). 

This growth is said to be driven by “broad-based unmet needs, demographics, and pharma’s proven ability to innovate”—factors that allow companies to manage healthcare spending effectively. 

The ability of the sector to continue delivering innovation while addressing pressing medical needs positions it for strong long-term growth, according to the firm

Compelling Valuation: “We believe the sector’s robust fundamentals are mispriced at the current low-20s discount to the global market,” said Bernstein.

As the market begins to recognize the true value of European pharma companies, Bernstein anticipates a potential re-rating that could drive future upside. The analysts also note that the sector’s defensive characteristics make it attractive in uncertain times, especially with the ongoing macroeconomic challenges.

Strong Cash Generation: The EU pharma sector is known for its “well-proven capital allocation track record,” according to the firm. 

Bernstein expects robust cash flow generation that will enable companies to fund productive R&D while maintaining strong dividend growth. 

They add that this financial strength gives companies the flexibility to pursue “disciplined/niche M&A” to further enhance their growth prospects.

Additionally, Bernstein highlights key drivers that could spur a re-rating of the sector, including stability in U.S. drug pricing, better pipeline execution, and the potential reform of U.S. Pharmacy Benefit Managers (PBMs).

 

This post appeared first on investing.com

Previous Post

Goldman Sachs’ 2025 outlook on cybersecurity stocks

Next Post

5 big analyst AI moves: Tesla, AMD, Adobe downgraded; Salesforce top pick for 2025

admin

admin

Next Post
5 big analyst AI moves: Tesla, AMD, Adobe downgraded; Salesforce top pick for 2025

5 big analyst AI moves: Tesla, AMD, Adobe downgraded; Salesforce top pick for 2025

Trending News

Why is Assassin’s Creed maker Ubisoft facing questions about its future?

Why is Assassin’s Creed maker Ubisoft facing questions about its future?

October 1, 2024
Top 4 S&P 500 stocks to buy Polymarket recession odds jump

Top 4 S&P 500 stocks to buy Polymarket recession odds jump

April 3, 2025
Saudi bourse extends rebound from 4-month low; Qatar falls

Saudi bourse extends rebound from 4-month low; Qatar falls

December 1, 2024
Subscribe to Insightful Word


    Recent News

    Nvidia shares fall on China sales exclusion, weaker data center sales: analysts weigh in

    Nvidia shares fall on China sales exclusion, weaker data center sales: analysts weigh in

    August 28, 2025
    SentinelOne stock price forecast ahead of earnings: buy or sell?

    SentinelOne stock price forecast ahead of earnings: buy or sell?

    August 28, 2025
    Tesla wants millions of robotaxis by 2025, but will Waymo win the long game?

    Tesla wants millions of robotaxis by 2025, but will Waymo win the long game?

    August 28, 2025
    Urban Outfitters stock slides 4% despite strong quarter on cautious outlook

    Urban Outfitters stock slides 4% despite strong quarter on cautious outlook

    August 28, 2025

    Recent News

    Nvidia shares fall on China sales exclusion, weaker data center sales: analysts weigh in

    Nvidia shares fall on China sales exclusion, weaker data center sales: analysts weigh in

    August 28, 2025
    SentinelOne stock price forecast ahead of earnings: buy or sell?

    SentinelOne stock price forecast ahead of earnings: buy or sell?

    August 28, 2025

    Latest News

    • Nvidia shares fall on China sales exclusion, weaker data center sales: analysts weigh in
    • SentinelOne stock price forecast ahead of earnings: buy or sell?
    • Tesla wants millions of robotaxis by 2025, but will Waymo win the long game?

    About Insightful Word

    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools
    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools

    Copyright © 2025 Insightfulword.com. All Rights Reserved.

    No Result
    View All Result
    • Investing
    • Stock
    • Economy
    • Politics

    Copyright © 2025 Insightfulword.com. All Rights Reserved.